Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Invested Capital (2017 - 2025)

Historic Invested Capital for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $265.5 million.

  • Autolus Therapeutics' Invested Capital fell 4434.56% to $265.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.5 million, marking a year-over-year decrease of 4434.56%. This contributed to the annual value of $427.3 million for FY2024, which is 28334.05% up from last year.
  • According to the latest figures from Q3 2025, Autolus Therapeutics' Invested Capital is $265.5 million, which was down 4434.56% from $346.5 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Invested Capital registered a high of $582.0 million during Q1 2024, and its lowest value of $111.5 million during Q4 2023.
  • For the 5-year period, Autolus Therapeutics' Invested Capital averaged around $315.3 million, with its median value being $284.9 million (2022).
  • Its Invested Capital has fluctuated over the past 5 years, first crashed by 6267.7% in 2023, then soared by 28334.05% in 2024.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Invested Capital stood at $313.3 million in 2021, then decreased by 4.67% to $298.7 million in 2022, then crashed by 62.68% to $111.5 million in 2023, then skyrocketed by 283.34% to $427.3 million in 2024, then tumbled by 37.88% to $265.5 million in 2025.
  • Its last three reported values are $265.5 million in Q3 2025, $346.5 million for Q2 2025, and $371.1 million during Q1 2025.